Comparing The Curative Effect And The Untoward Effect Of PLD With Epirubicin Treating Patients Of Breast Cancer In Adjuvant Chemotherapy

Objective:To investigate the efficacy and adverse reactions of the pegylated liposomes doxorubicin(PLD)compared with epirubicin in surgical patients with breast cacer.Methods:A retrospective analysis between January 1,2010 and January 1,2015 in Sir Run Run Shao Hospital was conducted.All of the patients are confirmed by pathological examination of breast cacer without metastasis.Among those patients,28 patients received chemotherapy contained PLD and the other 68 patients receive epirubicin.The curative effect and adverse reactions of those patients are analysised.Results:All the 28 patients treated with PLD survive and 2 patients treated with epirubicin died of breast cancer.The overall survival between these two groups is similar(p>0.05).The 3-year overall survival rate of PLD is 100%and epirubicin has the rate of 98.5%.7 patients receive PLD before surgery.The ORR is 100%,CR is 28.4%.However the ORR of epirubicin 97.4%and CR is 5.1%.The ORR and CR have no significant difference between these two groups(p>0.05).The mean left ventricular ejection fraction of reduces from 71.6%to 69.2%after patients are treated with PLD(p<0.05)while the mean LVEF of patients treated with epirubicin reduces from 70.4%to 68.4%(p<0.05).However,the reduction rates of LVEF affter treament between two groups have no significant difference.More patients with PLD(14.3%)suffer from grade 1 and 2 hand-foot syndrome than patients with epirubicin(0%)that nobody suffer any grade hand-foot syndrome(p<0.05).More grade 1 and 2 digestive adverse events occur in patients with epirubicin(32.3%)than PLD(3.6%),there is significant difference between these group(p<0.05).But,only 1 patient with epirubicin have a grade 3 or more digestive adverse event.There is no diference comparing hematologic toxicity of PLD to epirubicin(p>0.05).Conclusion:Comparing with epirubicin,patient treated with PLD as adjuvant or neoadjuvant chemotherapy obtain no more benefit in survival.PLD also can cause the reduction of LVEF similar as epirucibin.Both PLD and epirucibin have few hematologic adverse event.PLD has an advantage of causing less digestive adverse event,although most events of epirucibin don't need any clinic management.Hand-foot syndrome occur in patients with PLD while it is not very severe.In a word,PLD as a new form of antineoplastic drug have no sufficient advantages than epirubicin in adjuvant and neoadjuvant chemotherapy for breast cancer.